Drug intelligence / Profile preview

Apan

Development stage: Discontinued
Lead developer: GSK
Modality: Peptides
Administration: Intravenous

Overview

Apan (PPI-1019) is a peptide-based therapeutic developed by Praecis Pharmaceuticals for the treatment of Alzheimer's disease. It is a D-enantiomeric peptide derivative (Cholyl-LVFFA-NH2) designed to interact with beta-amyloid (Aβ) peptides. Its mechanism involves inhibiting the aggregation of Aβ and facilitating its clearance, thereby reducing nerve cell toxicity associated with amyloid plaques. Although it reached Phase II clinical trials and demonstrated safety and blood-brain barrier penetration, its development was voluntarily suspended in 2005 following a strategic restructuring at Praecis Pharmaceuticals.

Brand names: Apan
Other names: Cholyl-LVFFA-NH2Cholyl-LVFFA-NH-2Cholyl-LVFFA-NH 2

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on Apan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apan.

Explore the full profile